DCVax-Lの新興薬剤に関する洞察と市場予測：2032年

DCVax-Lは、患者の腫瘍組織から採取された腫瘍溶解液（腫瘍細胞を処理したタンパク質抽出液）からがん抗原を用いて作られます。そのため、DCVax-Lは腫瘍抗原のフルセットを組み込んでおり、上述のように腫瘍がそれを回避する方法（「エスケープ・バリアント」）を見つけることを困難にしています。これは、GBM脳腫瘍および卵巣がんの臨床試験で使用されたDCVax製品であり、現在第III相試験中です。DCVax-Lは、標準治療の一環として患者が外科的に腫瘍を摘出する状況において、あらゆる固形がんに対して使用されることが期待されます。

今後数年間で、多形性膠芽腫（GBM）の市場シナリオは、世界中の広範な研究と医療支出の増加により変化します。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、DCVax-Lの優位性に影響を与える可能性のある機会を模索しています。GBMを対象とした他の新興製品がDCVax-Lに厳しい市場競争をもたらすと予想され、近い将来、後発の新興治療薬が発売されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるDCVax-L市場について調査し、市場の概要とともに、2023年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 多形性膠芽腫（GBM）に対するDCVax-Lの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 DCVax-L市場評価

• GBMに対するDCVax-Lの市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国におけるGBMに対するDCVax-Lの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: DCVax-L, Clinical Trial Description, 2023
• Table 2: DCVax-L, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: DCVax-L Market Size in the 7MM, in USD million (2019-2032)
• Table 6: DCVax-L Market Size in the US, in USD million (2019-2032)
• Table 7: DCVax-L Market Size in Germany, in USD million (2019-2032)
• Table 8: DCVax-L Market Size in France, in USD million (2019-2032)
• Table 9: DCVax-L Market Size in Italy, in USD million (2019-2032)
• Table 10: DCVax-L Market Size in Spain, in USD million (2019-2032)
• Table 11: DCVax-L Market Size in the UK, in USD million (2019-2032)
• Table 12: DCVax-L Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: DCVax-L Market Size in the 7MM, USD million (2019-2032)
• Figure 2: DCVax-L Market Size in the United States, USD million (2019-2032)
• Figure 3: DCVax-L Market Size in Germany, USD million (2019-2032)
• Figure 4: DCVax-L Market Size in France, USD million (2019-2032)
• Figure 5: DCVax-L Market Size in Italy, USD million (2019-2032)
• Figure 6: DCVax-L Market Size in Spain, USD million (2019-2032)
• Figure 7: DCVax-L Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: DCVax-L Market Size in Japan, USD million (2019-2032)

“"DCVax-L Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about DCVax-L for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the DCVax-L for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the DCVax-L for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DCVax-L market forecast analysis for GBM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.

Drug Summary:

DCVax-L is made with cancer antigens from tumor lysate (a protein extract from processed tumor cells) from the patient's tumor tissue. As such, DCVax-L incorporates the full set of tumor antigens, making it difficult for tumors to find ways around it ("escape variants"), as described above. This is the DCVax product used in the GBM brain cancer and ovarian cancer clinical trials and is currently in the Phase III trial. DCVax-L is expected to be used for any solid tumor cancers in situations where the patient has their tumor surgically removed as part of standard care.

For DCVax-L, the monocytes are differentiated into dendritic cells and matured, activated, and loaded with biomarkers ("antigens") from the patient's tumor tissue (which is collected in a simple kit at the time of surgery to remove the tumor). The loading of biomarkers into the dendritic cells "educates" them about what the immune system needs to attack. The activated, educated dendritic cells are then isolated with very high purity and comprise the DCVax-L personalized vaccine. DCVax -L is administered to the patient through a simple intra-dermal injection in the upper arm, similar to a flu shot. The dendritic cells then convey the tumor biomarker information to the rest of the immune system agents (T cells, B cells, and others) as "marching orders," and the immune system agents fan out through the body, searching for anything with these biomarkers and attacking it.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the DCVax-L description, mechanism of action, dosage and administration, research and development activities in glioblastoma multiforme (GBM).
• Elaborated details on DCVax-L regulatory milestones and other development activities have been provided in this report.
• The report also highlights the DCVax-L research and development activities in GBM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around DCVax-L.
• The report contains forecasted sales of DCVax-L for GBM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for GBM.
• The report also features the SWOT analysis with analyst views for DCVax-L in GBM.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DCVax-L Analytical Perspective by DelveInsight

In-depth DCVax-L Market Assessment

This report provides a detailed market assessment of DCVax-L for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

DCVax-L Clinical Assessment

The report provides the clinical trials information of DCVax-L for GBM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for glioblastoma multiforme (GBM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DCVax-L dominance.
• Other emerging products for GBM are expected to give tough market competition to DCVax-L and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DCVax-L in GBM.
• Our in-depth analysis of the forecasted sales data of DCVax-L from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DCVax-L in GBM.

Key Questions:

• What is the product type, route of administration and mechanism of action of DCVax-L?
• What is the clinical trial status of the study related to DCVax-L in glioblastoma multiforme (GBM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DCVax-L development?
• What are the key designations that have been granted to DCVax-L for GBM?
• What is the forecasted market scenario of DCVax-L for GBM?
• What are the forecasted sales of DCVax-L in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to DCVax-L for GBM?
• Which are the late-stage emerging therapies under development for the treatment of GBM?

Table of Contents

1. Report Introduction

2. DCVax-L Overview in GBM

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. DCVax-L Market Assessment

• 5.1. Market Outlook of DCVax-L in GBM
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of DCVax-L in the 7MM for GBM
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of DCVax-L in the United States for GBM
  • 5.3.2. Market Size of DCVax-L in Germany for GBM
  • 5.3.3. Market Size of DCVax-L in France for GBM
  • 5.3.4. Market Size of DCVax-L in Italy for GBM
  • 5.3.5. Market Size of DCVax-L in Spain for GBM
  • 5.3.6. Market Size of DCVax-L in the United Kingdom for GBM
  • 5.3.7. Market Size of DCVax-L in Japan for GBM

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options